D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Also Read: Analyst Sees Wendy’s Playing Catch-Up, Needs Stronger Focus on Tech, Talent & Global Expansion Ocular Therapeutix has completed randomization in the first wet AMD trial, SOL-1.

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

TL;DR: AMD has launched the Ryzen 9 9950X3D and 9900X3D processors, featuring second-gen 3D V-Cache. The 9950X3D offers 16 cores, 32 threads, and a 5.7GHz boost, while the 9900X3D has 12 cores ...

The day is finally here: AMD is adding to its list of best processors, and gamers have something to be happy about — they both have the same recommended list price (MSRP) as their last-gen ...

The data from the phase 2 PRISM study comes from a cohort of 51 patients with wet or neovascular AMD, a form of the disease where abnormal blood vessels grow in the back of the eye. They all had ...

AMD Ryzen 9 9950X3D Review by Jacqueline Thomas "The AMD Ryzen 9 9950X3D might be the most powerful gaming processor on the market right now, but that doesn’t mean it has a de facto lead on ...

The port delivery system (PDS) formulation of ranibizumab – a VEGF inhibitor already approved as Lucentis to treat wet AMD – was able to extend the time between treatments for six months or ...

The topical treatment had no significant effect on total or central corneal fluorescence staining score.

Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).